1) The Alfred hospital Research & Ethics Unit
Latest Alfred Research Report
  Ling A, Dawkins R, Bailey M, Leung M, Cleland H, Serpell J, Kelly J. Short-term morbidity associated with sentinel lymph node biopsy in cutaneous malignant melanoma. Australas J Dermatol. 2010 Feb;51(1):13-7.

Ng JC; Swain S;. Dowling JP, Wolfe R, Simpson P, Kelly JW. The Impact of Partial Biopsy on Histopathologic Diagnosis of Cutaneous Melanoma: Experience of an Australian Tertiary Referral Service Arch Dermatol in press 2009

Handolias D, Salemi R, Murray W, Dobrovic A, Tan A, Liu W, Viros A, Kelly J, McArthur GA Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure Pigment Cell and Melanoma Research In Press 09

Kalkhoran S, Milne O, Zalaudek, Puig, S, Malvehy J, Kelly JW, Marghoob AA .Historical, clinical, and dermoscopic characteristics of thin nodular melanoma Arch Dermatol in press 2009

Cust AE; Schmid H; Maskiell JA; Jetann J; Ferguson M;. Holland EA; Agha-Hamilton C;. Jenkins MA; Kelly J;. Kefford RF;. Giles GG; Armstrong BK;. Aitken JF; Hopper JL;. Mann GJ. Population-based, Case-Control-Family Design to Investigate Genetic and Environmental Influences on Melanoma Risk: Australian Melanoma Family Study American Journal of Epidemiology 2009; doi: 10.1093/aje/kwp307

Pan Y, Kelly JW. How to Treat Melanoma. Australian Doctor; 20/11/09


1. Pan Y, Chamberlain AJ, Bailey M, Chong AH, Haskett M, Kelly JW.
Dermatoscopy aids in the diagnosis of the solitary red scaly patch or plaque -  features distinguishing superficial basal cell carcinoma, intraepidermal carcinoma, and psoriasis.
J Am Acad Dermatol. 2008 Aug; 59: 268-274

2. W Liu, GA McArthur, M Trivett , WK Murray, R Wolfe, JW Kelly.
Subjective self-reported melanoma growth rate correlates with objective tumour proliferation markers.
Arch Dermatol 2008 Apr 144(4): 555-6


1. Kelly JW, Henderson MA, Thursfield VJ, Slavin J, Ainslie J, Giles G.
The management of primary cutaneous melanoma in Victoria in 1996 and 2000.
Med J Aust 2007; 187: 511-514

2.  Chamberlain AJ, Kelly JW.
Use of dermoscopy in Australia. (letter)
Med J Aust. 2007 Aug 20;187(4):252-3

3. Liu W, Kelly JW, Trivett M, Murray WK, Dowling JP, Wolfe R, Mason G, Magee J, Angel C, Dobrovic A, McArthur GA.
Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma.
J Invest Dermatol. 2007 Apr;127(4):900-5. Epub 2006 Dec 7.

4. J.W. Kelly, G.A. McArthur, R. Wolfe, J.F. Thompson, W. Liu.
In reply, Fast growing and slow growing melanomas.
Arch Dermatol 2007;143:803-4

5. J.W. Kelly, G.A. McArthur, R. Wolfe, J.F. Thompson, W. Liu. 
In reply, A confusing message will not improve the detection of melanoma.
Arch Dermatol 2007;143:806-7


1. Liu W, Dowling JP, Murray WK, McArthur GA, Thompson JF, Wolfe R, Kelly JW.
Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas.
Arch Dermatol. 2006 Dec;142(12):1551-8.

2. Chamberlain AJ, Kelly JW.
Partial biopsy of pigmented lesions: proceed with caution.
Australas J Dermatol. 2006 Feb;47(1):73-4 

3. Roberts H, Haskett M, Kelly JW.
Melanoma – clinical features and techniques for early diagnosis.
Medicine Today January 2006


1: Dolianitis C, Kelly J, Wolfe R, Simpson P.
Comparative performance of 4 dermoscopic algorithms by nonexperts for the diagnosis of melanocytic lesions.
Arch Dermatol. 2005 Aug;141(8):1008-14.

2: Menzies SW, Bischof L, Talbot H, Gutenev A, Avramidis M, Wong L, Lo SK, Mackellar G, Skladnev V, McCarthy W, Kelly J, Cranney B, Lye P, Rabinovitz H, Oliviero M, Blum A, Varol A, De'Ambrosis B, McCleod R, Koga H, Grin C, Braun R, John R.
The performance of SolarScan: an automated dermoscopy image analysis instrument for the diagnosis of primary melanoma.
Arch Dermatol. 2005 Nov;141(11):1388-96

3: Liu W, Hill D, Gibbs AF, Tempany M, Howe C, Borland R, Morand M, Kelly JW.
What features do patients notice that help to distinguish between benign pigmented lesions and melanomas?: the ABCD(E) rule versus the seven-point checklist.
Melanoma Res. 2005 Dec;15(6):549-54.

4 Banky JP, Kelly JW, English DR, Yeatman JM, Dowling JP.
Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma.
Arch Dermatol. 2005 Aug;141(8):998-1006.

5: Kelly JW.
Nodular melanoma: how current approaches to early detection are failing.
J Drugs Dermatol. 2005 Nov-Dec;4(6):790-3

6. Kelly JW.
Malignant melanomas - how many have you missed?
In Marks R. MJA Practice Essentials: Dermatology. Second Edition, 2005
  1. Kelly JW.
Nodular melanoma: How current approaches to early detection are failing.
The Melanoma letter, Skin Cancer Foundation, New York,  June 2004

1. Chamberlain AJ, Fritschi L, Kelly JW.
Nodular melanoma: Patient’s perceptions of presenting features and implications for early detection.
J Am Acad Dermatol 2003; 48 (3):

2. Chamberlain AJ, Fritschi L, Giles GG, Dowling JP, Kelly JW.
Nodular melanoma is not a distinct entity
(Letter) Arch Dermatol 2003; 139: 387-388

3. Serpell JW, Carne PWG, Bailey M.
Radical lymph node dissection for melanoma
ANZ J Surg 2003; 73: 294-299

4. Kelly JW, Chamberlain AJ, Staples MP, McAvoy B.
Nodular melanoma. No longer as simple as ABC
Australian Family Physician. 2003; 32(9):706-709


1. Chamberlain AJ, Fritschi L, Giles GG, Dowling JP, Kelly JW.
Nodular type and older age are the most significant associations of thick melanoma in Victoria, Australia.
Arch Dermatol 2002; 138: 609-614

  1. Ang CG, Kelly JW, Fritschi L, Dowling JP.
Characteristics of familial and non-familial melanoma in Australia.
Melanoma Research 1998; 8: 459-464

1. Orchard DC, Dowling JP, Kelly JW.
Spitz naevi misdiagnosed histologically as melanoma: Prevalence and clinical profile
Australas J Dermatol 1997; 38: 12-14

  Other Relevant Melanoma Publications From The VMS Staff

1. Chamberlain AJ, Ng J. Cutaneous melanoma: atypical variants and presentations. Australian Family Physician. 2009:38:476-82

2. Chamberlain AJ, Kelly JW. Nodular melanoma and older men: a major challenge for community surveillance programs. [letter]Med J Aust 2004;180(8):432

3. Chamberlain AJ. Nodular melanoma – controversies and considerations for containment. [letter] Dermatol Surg 2005;31(8 Pt  1):979

4 .  MacLennan R, Kelly JW, Rivers JK, Harrison SL.
The Eastern Australian Childhood Nevus Study: Site differences in density and size of melanocytic nevi in relation to latitude and phenotype.
J Am Acad Dermatol. 2003; 48:367-375

5. Harrison SL, Buettner PG, MacLennan R, Kelly JW, Rivers JK.
How good are parents at assessing melanocytic naevi on their children? A study comparing parental counts, dermatologist counts, and counts obtained from photographs.
Am J Epidemiol 2002; 155: 1128-1136

6. Kelly JW, Dowling JP 
Melanoma in the elderly – A neglected public health challenge
Letter (reply) Med J Aust 1999; 170: 394-395

7. MacLennan R, Kelly JW, Martin NG.
Melanocytic Naevi in Eastern Australia – latitude is important but most variation is within cities.
Letter Australas J Dermatol 1999; 40, 167-168

8.  Kelly JW.
Melanoma in the elderly – A neglected public health challenge.
Med J Aust 1998; 169: 403-404

9. Kelly JW, Yeatman JM, Regalia C, Mason G, Henham AP.
A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance.
Med J Aust 1997; 167: 191-194

10. McCormack CJ, Kelly JW, Dorevitch AP.
Basal Cell Carcinoma: Differences in age and body site distribution of the histological subtypes of basal cell carcinoma: A possible indicator of differing aetiologies.
Arch. Dermatol 1997; 133: 593-596

11. Kelly JW.
How many melanomas have I missed? Is this the question?  
Letter (reply)  Med J Aust 1996; 165: 456

12. Kelly JW.
Malignant melanomas - how many have you missed?
In Marks R. MJA Practice Essentials: Dermatology. 1996: 43-48

13. Rivers JK, Maclennan R, Kelly JW, Lewis AE, Tate BJ, Harrison S, McCarthy WH.
The Eastern Australian childhood nevus study: prevalence of atypical nevi, congenital nevus‑like nevi, and other pigmented lesions.
J Am Acad Dermatol 1995; 32: 957-63

14. Kelly JW, Rivers JK, MacLennan R, Harrison S, Lewis A, Tate B.
Sunlight ‑ A major factor associated with the development of melanocytic nevi in Australian schoolchildren
J Am Acad Derm, 30: 40‑48, 1994

15. Holly EA, Kelly JW, Ahn DK, Shpall SN, Rosen JI.
Risk of cutaneous melanoma by number of melanocytic nevi and correlation of nevi by anatomic site. In Gallagher RP, Elwood JM, eds. Epidemiological aspects of cutaneous malignant melanoma.
Boston: Kluwer Academic Publishers, 1994: 159‑174

16. Kelly JW.
Melanoma: detection and management
Aust Fam Physician, 23: 801‑812, 1994

17. Kelly JW.
Following lentigo maligna may not prevent the development of life threatening melanoma
Arch Dermatol, 128: 657‑ 660, 1992

18. Kelly JW, Sabto J, Gurr FW, Bruce F.
Retinoids to prevent skin cancer in organ transplant recipients
Lancet, 338: 1407, Nov. 30, 1991

19. English DR, MacLennan R, Rivers J, Kelly JW, Armstrong BK.
Epidemiological studies of melanocytic naevi: Protocol for identifying and recording naevi.
International Organisation for Research on Cancer, World Health Organisation, Report No. 90/002, Nov 1990

20. Kelly JW, Holly E, Shpall S, Ahn DK.
The distribution of melanocytic nevi in melanoma patients and control subjects.
Aust. J. Derm., 30: 1‑8, 1989

21. Holly EA, Kelly JW, Shpall SN, Shu‑Hui C.
Number of melanocytic nevi as a major risk factor for malignant melanoma
J Am Acad Derm, 17, 3, 459 ‑468, 1987

22. Kelly JW, Crutcher WA, Sagebiel RW.
The clinical diagnosis of dysplastic melanocytic nevi ‑ a clinicopathologic correlation.
J Am Acad Derm, 14, June 1986.

23. Kelly JW.
Primary cutaneous malignant melanoma ‑ Diagnosis and management.
Aust. Family Physician, July, 1986.

24. Sagebiel RW, Kelly JW, Blois MS.
The influence of time and the reexcision of melanoma
J Am Acad Derm 14: 855, 1986 (letter, reply)

25. Kelly JW, Sagebiel RW, Blois MS.
Regression in malignant melanoma ‑ A histological feature without independent prognostic significance.
Cancer 56: 2287‑2291, 1985
26. Kelly JW, Sagebiel RW, Clyman S, Blois MS.
Thin level IV malignant melanoma ‑ a subset in which level is the major prognostic indicator.
Ann Surg 202: 98‑103, 1985

27. Kelly JW, Blois MS, Sagebiel RW.
Frequency and duration of patient follow‑up after treatment of a primary malignant melanoma.
J Am Acad Derm 13: 756‑760, 1985

28. Kelly JW, Sagebiel RW, Calderon W, Murillo L, Dakin RL, Blois MS. 
The frequency of local recurrence and microsatellites as a guide to reexcision margins for cutaneous malignant melanoma.
Ann Surg 200: 759‑763, 1984

  2) Clinical Trials and Lead Clinicians

A  Multicentre Selective Lymphadenectomy Trial II – Mr Richard Bloom

B  ANZMTG trial of Whole Brain Radiotherapy – Dr Jeremy Ruben

C   Aldara for Lentigo Maligna – Dr Martin Haskett

D   Ipilimumab for Metastatic Melanoma – Dr Andrew Haydon

E  Early diagnosis of melanoma using expression profiling and non-invasive sampling of skin cells – Dr Alex Chamberlain
  Victorian Melanoma Service : the Alfred Hospital, Commercial Rd Prarhan